Lipoic Acid Mineral Complex (LAMC) is the most active ingredient in a dietary supplement called Poly MVA. In the LAMC formulation, reduced lipoic acid is bound to the antioxidant alpha-lipoic acid, creating a potent redox polymer that is like a water soluble vitamin. In addition to LAMC, this proprietary blend is formulated with minerals, vitamins and amino acids such as molybdenum, rhodium, ruthenium, thiamine, riboflavin, cyanocobalamin, acetyl cysteine, and folic acid. Redox polymers are very efficient at accepting and transferring charge (electrons), which is the basis of cellular metabolism. A unique characteristic of cancer cells is that they have a disrupted metabolism. Maligned cells favor an anaerobic metabolism (red oval in figure below) and formyl methionine. The largest integrative cancer investigation of LAMC supplement was an open-label, Veterinary oncology program with over 900 dogs enrolled, since its inception in January 2004. Patients received the PdLA supplement (Poly MVA) as part of their chemotherapy, radiation and/or surgical protocol at a dosage of 1 ml/s lbs.  PdLA twice daily (equivalent human dosage of approximately 8 tsp). The findings were most effective in the following solid tumors: soft tissue sarcoma, hemangiosarcoma, mast cell, transition cell carcinoma, lung, and sac carcinoma, renal carcinoma, squamous cell carcinoma, fibrosarcoma, melanoma, merlinoma, neuroblastoma, mammary adenocarcinoma.

EXAMPLE: Veterinary Osteosarcoma Data
- PdLA improved median survival 62% (103 days) compared to surgery alone.
- PdLA added to the chemotherapy regimen (carboplatin + doxorubicin) resulted in a 27% (79 days) longer median survival, with improved objective parameters (i.e. weight, anemia, liver and kidney function).

Fatigue

Scientific Published Studies
- Multiple Sclerosis associated Fatigue – Stony Brook University
  - An IND study was recently completed in which each patient took 4 teaspoons Poly MVA per day for 6 weeks. The patients were tested at their baseline visit and at the end of 6 weeks using three Multiple Sclerosis Fatigue Scales (Fatigue Severity Scale (FSS); PROMIS Fatigue; Multiple Sclerosis Fatigue Impact Scale (MSFIS)). There was a statistically significant decrease in each scale, leading the Principle Investigators to conclude that the product was “well tolerated and was associated with a clear reduction in fatigue severity and fatigue impact.”

CIPLA Pharmaceuticals

Palliative Care Study
- The following EORTC QLQ C30 parameters demonstrated statistically significant patient improvement: Cognitive Functioning, Emotional Functioning, Social Functioning, Fatigue, Sleep Disturbances and Appetite Loss.

In contrast, LAMC facilitates aerobic metabolism since thiamine and lipoic acid act as cofactors in the conversion of pyruvate at Complex I of the mitochondria, which targets LAMC’s energy to the aerobic cascade (figure above). Our research has focused on LAMC as a metabolically-targeted therapy to potentiate radio and chemotherapy, alleviate fatigue, and protect normal cells from radiation damage.

Scientific Published Studies
- The electrical findings that the LAMC supplement Poly MVA demonstrates a robust redox capacity has led to a significant number of publications on its ability to reduce the harmful effects of radiation exposure. Peer reviewed findings have demonstrated its significant ability to: protect and repair DNA, offer chromosome protection, have anti-oxidant activity, increase spleen colony formation, as well as, attenuate radiation induced weight loss (El-Marakby et al., 2013, a & b; Selim et al., 2012, a & b; Desouky et al., 2012; Menon and Nair, 2011; Ramachandran et al., 2010; Menon et al., 2009).

Lipoic Acid Mineral Complex: A Novel Metabolic Molecule in Integrative Therapies

Frank Antonovich, Ph D1,2 ; Albert Sanchez3
1Garnett McKeen Laboratory, N.Y.; 2St. Joseph’s College, N.Y.; 3AMARC Enterprises, Inc., CA

From 2004-2006 Dr. James Forsythe studied 225 stage IV cancer patients (multiple origins). Treatment of IV Poly MVA + chemotherapy provided a 6 year Overall Survival rate of 32%, while the average 5 year survival rate is 2.1% in all stage IV cancers, as reported in the Clinical Journal of Oncology. Currently, Dr. Forsythe’s is now utilizing genetic chemosensitivity testing, immuno therapy, in situ-potentiating therapy, along with Poly MVA to enhance his results. The patients are discharged on oral Poly MVA and targeted treatments, with follow up every 3 months. Thus far, 39% of Dr. Forsythe’s patients have reached 40 months in the study.

Amputation w/ Chemotherapy
Amputation w/ Poly MVA (n=11)
Amputation Alone (n=162)

Amputation w/ Chemotherapy

© 2016 AMARC Enterprises, Inc. All rights reserved. No part of this material may be reproduced in any form without the prior written consent of AMARC Enterprises.